Redwood Pharma looks to share developments regarding its RP501 and RP101 therapies for treatment of dry eye disease with potential clinical and commercial partners.

To schedule a meeting please contact:

Martin Vidaeus, CEO

Martin.vidaeus@redwoodpharma.com

RP501 - a differentiated therapy addressing a large market

RP501 has significant therapeuticand commercialpotentialas a next-generation first-line therapy to treat the majority of DED sufferer, including males and females of all ages. The global marketwasvalued at US$2.3 billion in 2019 and expected to grow to US$2.9 billion by 2030 (Source: Transparency Market Research 2020). Today,DED sufferersturn first to artificial tears (saline eye drops) to provide temporary relief.

Regular eye drops are,however,quickly cleared from the front of the eye and need frequent reapplication, creating a need for products that stay longer on the eye and reduce the number of drops to provide daily relief.

RP501 (IntelliGel) was used as the vehicle (placebo control) in the RP101 Phase II clinical trial completed last year, and our data from the RP101 trial showed that twice daily administration of RP501 improved both symptoms and objective measures of DED, inpost-menopausal womenwith severe disease. In this trial, RP501 demonstrated increased tear fluid production as measured by the Schirmer test. Likewise, it improved various symptoms including foreign body sensation and dryness. RP501, as an easy-to-apply alternative to artificial tears providing long-lasting relief with fewer instillations per day, may thus offer a convenient and differentiated solution to over 340 million people worldwide suffering from DED.

RP101 - a targeted therapy for moderate-to-severe dry eye in post-menopausal women

RP101 has demonstrated safety and efficacy in a Phase II clinical trial in Europe. Based on an estrogen analogue tested in two previous Phase II trials in the US, RP101 demonstrated significant efficacy in both objective and subjecive endpoints and is ready for further development in a Phase III clinical trial. There are an estimated 10 million post-menopausal women in the US and EU the suffer from chronic, moderate-to-sever dry eye disease. Today there are no adequate therapies to help this large underserved market segment. Whereas current medications unsuccessfully try to resolve only the symptoms of dry eye, RP101 targets an underlying biological mechanism and cause of the disease.

About Redwood Pharma

Redwood Pharma develops ophthalmic products for unmet medical needs through novel approaches. In providing commercial partners and their customers with effective medical solutions, the Company is currently developing treatments for dry eye disease in various target patient populations. The RP101 program targets moderate-to-severe dry eye disease in post-menopausal women by delivering a low-dose estrogen therapy to the front of the eye. The RP501 program aims to treat milder forms of dry eye in a broader patient population including both men and women of all ages. For other potential drug substances and therapeutic areas, the Company can employ the IntelliGel drug delivery platform that enhances patient convenience by controlling dosing and potentially reducing the number of instillations per day and subsequent side-effects. Redwood Pharma leverages its strengths in early clinical development and aims to generate revenues through, among others, licensing agreements with companies that have capabilities to manufacture and sell medical products worldwide.

Redwood Pharma AB (publ) is listed on the Nasdaq First North Growth stock market (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit:www.redwoodpharma.com